Literature DB >> 20581580

Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.

Shih-Chieh Chang1, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20581580     DOI： 10.1097/JTO.0b013e3181dc39cd

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  10 in total

Review 1.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

2.  Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Authors:  Christopher D Jakubowski; Andrew J Plodkowski; Jason C Chang; Natasha Rekhtman; Afsheen Iqbal; Paul K Paik; Helena A Yu
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

Review 3.  EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

Authors:  Xavier Cansouline; Béatrice Lipan; Damien Sizaret; Anne Tallet; Christophe Vandier; Delphine Carmier; Antoine Legras
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

4.  Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease.

Authors:  Kosuke Kashiwabara; Hiroshi Semba; Shinji Fujii; Shinsuke Tsumura
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

5.  Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease.

Authors:  Qing Tian; Liang-An Chen
Journal:  Case Rep Oncol       Date:  2011-09-16

6.  Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma.

Authors:  Sang Hoon Yoo; Jin Ah Ryu; Seo Ree Kim; Su Yun Oh; Gu Sung Jung; Dong Jae Lee; Bong Gyu Kwak; Yu Hyun Nam; Kyung Hyun Kim; Young Jun Yang
Journal:  Korean J Fam Med       Date:  2016-11-18

7.  Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.

Authors:  Tatsunori Kiriu; Daisuke Tamura; Motoko Tachihara; Reina Sekiya; Daisuke Hazama; Masahiro Katsurada; Kyosuke Nakata; Tatsuya Nagano; Masatsugu Yamamoto; Hiroshi Kamiryo; Kazuyuki Kobayashi; Yoshihiro Nishimura
Journal:  Intern Med       Date:  2017-10-16       Impact factor: 1.271

8.  Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.

Authors:  Hironori Uruga; Shuhei Moriguchi; Yui Takahashi; Kazumasa Ogawa; Kyoko Murase; Sayaka Mochizuki; Shigeo Hanada; Hisashi Takaya; Atsushi Miyamoto; Nasa Morokawa; Kazuma Kishi
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

9.  The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer.

Authors:  Shih-Chieh Chang; Cheng-Yu Chang; Jin-Yuan Shih
Journal:  Cancers (Basel)       Date:  2011-06-10       Impact factor: 6.639

10.  Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma.

Authors:  Shingo Satoh; Takayuki Shiroyama; Motohiro Tamiya; Shingo Nasu; Ayako Tanaka; Satomu Morita; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Tomonori Hirashima
Journal:  Respir Med Case Rep       Date:  2017-12-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.